

MCI CLINICAL TRIALS ACTIVITY

10/1/2019 TO 9/30/2020

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	BUDGET PERIOD		BUDGET AWARDS
UNIT: Mitchell Cancer Institute								
MCI Clinical Trials								
Alkharabsh	Omar	SGI	A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral	A20-0089-001	New	1/1/2020	9/30/2020	\$19,500
Cohen,	Michael	NIH	Cardioprotection by inhibition of coagulation and inflammation in myocardial infarction	A18-0157-003	Continuation	10/1/2019	9/30/2020	\$3,750
Dyess,	Donna	GNTC	B59	A18-0198-003	Continuation	2/1/2020	9/30/2020	\$23,790
Dyess,	Donna	LUMI	MCI CT Lumicell Breast Trial	A18-0209-003	Continuation	10/1/2019	9/30/2020	\$13,227
Dyess,	Donna	LUMI	Lumicell Pivotal Trial	A19-0230-001	New	1/1/2019	9/30/2020	\$27,670
Khushman,	Moh'D	PILLC	MM-398-07-02-03: A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)- containing Regimens versus nab-paclitaxel	A18-0163-002	Continuation	1/1/2020	9/30/2020	\$34,540
Khushman,	Moh'D	MERCK	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants	A20-0031-001	New	11/1/2019	9/30/2020	\$25,355
Khushman,	Moh'D	ABVI	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-	A20-0061-001	New	2/1/2020	9/30/2020	\$17,875
Khushman,	Moh'D	IPSEN	An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel	A20-0125-001	New	6/1/2020	9/30/2020	\$12,000
Khushman,	Moh'D	ASTZ	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With	A20-0202-001	New	8/10/2020	9/29/2021	\$0
Khushman,	Moh'D	NIH	Phase I/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)	A20-0205-001	New	6/1/2020	5/31/2021	\$0
Khushman,	Moh'D	ASTZ	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with	A20-0206-001	New	9/30/2020	9/29/2021	\$0
Khushman,	Moh'D	ABVI	MCI Abbvie M16-289 TAHOE	A17-0178-003	Continuation	6/1/2020	9/30/2020	\$14,587

MCI CLINICAL TRIALS ACTIVITY

10/1/2019 TO 9/30/2020

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	BUDGET PERIOD	BUDGET AWARDS
Norden,	Norma	CALBIO	Calithera Bioscience CX-839-007 UAB TNBC	A 17-0176-003	Continuation	8/1/2019 9/30/2020	\$5,283
Pai,	Sachin	SWOG	SWOG S1609 DART	A 17-0075-001	New	4/12/2017 4/12/2018	\$9,000
Pai,	Sachin	SWOG	SWOG S1609 DART	A 17-0075-002	Continuation	10/1/2019 9/30/2020	\$7,200
Pai,	Sachin	CALBIO	Calithera INCB 01158-101 Solid Tumor	A 18-0048-004	Continuation	10/1/2019 9/30/2020	\$68,128
Pai,	Sachin	ABT	MCI CAEB1102-101B Lung	A 18-0210-003	Continuation	10/1/2019 9/30/2020	\$100
Pai,	Sachin	INC	A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects	A 19-0035-003	Continuation	10/1/2019 9/30/2020	\$197,024
Pai,	Sachin	NIH	LUNGMAP, A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-	A 19-0247-001	New	3/11/2019 9/30/2020	\$7,853
Pai,	Sachin	NIH	LUNG-MAP SUB-STUDY S1900A: A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH- OR BRCA- POSITIVE STAGE IV	A 19-0248-001	New	4/25/2019 9/30/2020	\$5,140
Pai,	Sachin	NIH	S1800A: A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF	A 19-0249-001	New	7/19/2019 7/16/2021	\$0
Pai,	Sachin	NIH	SWOG 1602 BCG	A 20-0027-001	New	1/1/2020 9/30/2020	\$3,000
Pai,	Sachin	MERCK	MCI Merck 5890-001 Ph 1 Solid Tumor	A 20-0033-001	New	11/25/2019 9/30/2020	\$181,005
Pai,	Sachin	NIH	S1900C, A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer	A 20-0139-001	New	2/3/2020 9/30/2020	\$2,500
Pai,	Sachin	NIH	S1400F, A Phase II Study of MEDI4736 (durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1	A 20-0140-001	New	11/1/2019 10/29/2021	\$0
Poosarla,	Teja	PILLC	A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT	A 19-0232-001	New	5/14/2019 9/30/2020	\$14,400

MCI CLINICAL TRIALS ACTIVITY

10/1/2019 TO 9/30/2020

DEPT	PI	AGENCY	PROJECT TITLE	AWARD NUMBER	SUBMISSION TYPE	BUDGET PERIOD		BUDGET AWARDS
Poosarla,	Teja	GNTC	A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH	A20-0090-001	New	1/29/2020	9/30/2020	\$27,422
Poosarla,	Teja	SGI	SGNTUC-016 HER2+	A20-0107-001	New	1/1/2020	9/30/2020	\$17,500
Poosarla,	Teja	BMSI	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant	A20-0124-001	New	6/1/2020	9/30/2020	\$17,250
Rocconi,	Rodney	NIH	Clinical Trial ECOG - 1967	A13-0003-003	Continuation	10/1/2019	9/30/2020	\$2,250
Rocconi,	Rodney	NRG	Member Institution Purchased Service Agreement NRG Oncology Foundation, Inc.	A14-0009-002	Continuation	3/1/2019	2/28/2021	\$22,100
Rocconi,	Rodney	CARIS	Caris retrospective data collection trial agreement	A17-0228-002	Continuation	10/1/2019	9/30/2020	\$2,000
Rocconi,	Rodney	MERCK	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of	A20-0030-001	New	11/1/2019	9/30/2020	\$214,419
Rocconi,	Rodney	EXE	CABO - A phase II Study of Cabozantinib for Recurrent, or Persistent Cervical Cancer	A20-0108-001	New	10/1/2019	9/30/2020	\$42,613
Rocconi,	Rodney	PPD	High Performance Site Initiative (HPSI)	A20-0219-001	New	9/1/2020	9/1/2020	\$46,800
Scalici,	Jennifer	NIH	NRG GY006 Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer	A20-0071-001	New	1/1/2020	12/31/2020	\$0
Wilson,	Felicia	SBLD	Children's Oncology GroupFunded by Saint Baldrick's Foundation	A12-0002-003	Continuation	10/1/2019	9/30/2020	\$8,950
TOTAL FOR DEPARTMENT: MCI Clinical Trials								\$1,094,231